



1. Nrf2 protein expression in TQ treated INF-γ stimulated MDA-MB-231 TNBC cells

A.




Peaks		Capillaries										
Sample	Prim...	Cap	Peak	Name	Positi...	MW (...)	Height	Area	% Area	Width	S/N	Baseline
Control1	Nrf2	8	1		627	116	308.1	5587.7		17.0	40.0	40.8
Treated1	Nrf2	10	1		624	121	477.6	2030...		39.9	11...	55.9
Stimulant1	Nrf2	15	1		620	104	144.9	1604.5		10.4	27.7	56.6
Cotreated1	Nrf2	19	1		624	109	351.7	1187...		31.7	79.4	33.8

B.




C.




**Supplement Figure S1.** Nrf2 protein expression in TQ treated INF-Y stimulated MDA-MB-231 TNBC cells. Following the overnight incubation period, cells were equally treated with 15  $\mu$ M of TQ for 24. A. Blot for Nrf2 protein expression in control, treated, stimulated and cotreated MDA-MB-231 cell. B. Blot for protein expression of GAPDH used for normalization. C. Blot for Nrf2 protein expression in control and TQ treated MDA-MB-231 cell in triplicates.

2. Nrf2 protein expression in TQ treated INF-γ stimulated MDA-MB-468 TNBC cell

A.




B.



Peaks												
Capillaries												
Sample	Prim...	Cap	Peak	Name	Positi...	MW (...)	Height	Area	% Area	Width	S/N	Baseline
control	GAP...	21	1		543	42	2010...	1684...		7.9	13...	23.3
Treated1	GAP...	22	1		543	42	7650.5	6383...		7.8	35...	20.5
Stimulant1	GAP...	23	1		543	42	1466...	1204...		7.7	74...	35.0
CoTreated1	GAP...	24	1		545	42	1493...	1245...		7.8	15...	7.5
0.1X samp...	GAP...	25	1		544	41	5.8	265.9		43.0	39.5	2.2


C.



**Figure S2.** Nrf2 protein expression in TQ treated INF- $\gamma$  stimulated MDA-MB-468TNBC cells. Following the overnight incubation period, cells were equally treated with 15  $\mu$ M of TQ for 24. A. Blot for Nrf2 protein expression in control, treated, stimulated and cotreated MDA-MB-468 cell. B. Blot for protein expression of GAPDH used for normalization. C. . Blot for Nrf2 protein expression in control, treated, stimulated and cotreated MDA-MB-468 cell in different replicates.


3. PD-L1 protein expression in TQ treated INF-γ stimulated MDA-MB-231 TNBC cells

A



Peaks		Capillaries										
Sample	Prim...	Cap	Peak	Name	Positi...	MW (...)	Height	Area	% Area	Width	S/N	Baseline
Control1	PDL-1	8	1		610	78	1726.5	2523...		13.7	13...	126.4
Stimulant1	PDL-1	16	1		457	14	500.9	1595...		29.9	91.6	98.2
Stimulant1	PDL-1	16	2		591	62	679.1	2207...		30.5	10...	137.5
Stimulant1	PDL-1	16	3		607	78	2092.5	7529...		33.8	22...	144.9
Cotreated1	PDL-1	19	1		589	59	556.4	1368...		23.1	45.0	121.4
Cotreated1	PDL-1	19	2		617	82	726.7	2135...		27.6	27.2	124.8
Cotreated1	PDL-1	19	3		655	146	541.5	1569...		27.2	29.8	128.0


B.



Peaks		Capillaries										
Sample	Prim...	Cap	Peak	Name	Positi...	MW (...)	Height	Area	% Area	Width	S/N	Baseline
Control	GAP...	21	1		500	26	208.8	2000.0		9.0	68.2	46.3
Control	GAP...	21	2		543	39	2265...	1971...		8.2	91...	46.7
Control	GAP...	21	3		632	114	2711.8	3994...		13.8	24...	47.7
Control	GAP...	21	4		653	155	2279.6	3132...		12.9	19...	47.9
treated1	GAP...	22	1		550	40	1394...	1194...		8.0	43...	46.0
treated1	GAP...	22	2		613	82	545.2	7492.3		12.9	26.6	49.3
treated1	GAP...	22	3		625	98	805.1	1229...		14.3	29.4	50.0
treated1	GAP...	22	4		653	147	1214.2	2036...		15.8	10...	51.7
stimulant	GAP...	23	1		500	26	695.8	7015.5		9.5	23...	17.0
stimulant	GAP...	23	2		543	39	2276...	1957...		8.1	83...	14.0
stimulant	GAP...	23	3		606	77	1462.0	2044...		13.1	35.5	12.4
stimulant	GAP...	23	4		622	109	1990.1	2903...		13.7	30.4	12.4
stimulant	GAP...	23	5		647	145	1822.7	2554...		13.2	13...	12.8
CoTreated1	GAP...	24	1		548	40	1639...	1396...		8.0	59...	30.8
CoTreated1	GAP...	24	2		621	100	1001.6	1360...		12.8	43.1	34.1
CoTreated1	GAP...	24	3		648	141	1045.4	1392...		12.5	10...	35.3
0.1X sampl...	GAP...	25	1		547	39	46.9	1557.9		31.2	12...	1.6

C.







**Figure 3.** PD-L1 protein expression in TQ treated INF-Y stimulated MDA-MB-231 TNBC cells. Following the overnight incubation period, cells were equally treated with 15  $\mu$ M of TQ for 24. A. Blot for PD-L1 protein expression in control, treated, stimulated and cotreated MDA-MB-231 cell. B. Blot for protein expression of GAPDH used for normalization.

4. PD-L1 protein expression in TQ treated INF-γ stimulated MDA-MB-468 TNBC cells

A.




B.



Peaks		Capillaries										
Sample	Prim...	Cap	Peak	Name	Positi...	MW (...)	Height	Area	% Area	Width	S/N	Baseline
Control1	GAP...	19	1		491	26	319.9	3073.5		9.0	69.7	96.8
Control1	GAP...	19	2		532	38	1933...	1758...		8.5	52...	101.2
Control1	GAP...	19	3		627	115	3057.8	3373...		10.4	26...	107.8
Control1	GAP...	19	4		678	226	1011...	1191...		11.1	80...	109.9
Control1	GAP...	19	5		690	249	1165...	1427...		11.5	10...	110.3
Treated2	GAP...	21	1		539	40	1534...	1306...		8.0	37...	89.3
Treated2	GAP...	21	2		608	90	1086.7	1984...		17.2	24.6	101.5
Treated2	GAP...	21	3		648	158	1444.8	2823...		18.4	31.1	106.9
Treated2	GAP...	21	4		682	229	3295.1	7269...		20.7	24...	110.9
Stimual...	GAP...	22	1		490	26	441.2	4471.8		9.5	16...	64.7
Stimual...	GAP...	22	2		536	39	1795...	1632...		8.5	72...	90.9
Stimual...	GAP...	22	3		582	60	366.1	4256.2		10.9	20.3	124.1
Stimual...	GAP...	22	4		628	117	1249.5	1711...		12.9	67.4	162.2
Stimual...	GAP...	22	5		646	149	1098.0	1456...		12.5	44.8	178.0
Stimual...	GAP...	22	6		678	225	1891.7	2915...		14.5	26...	206.8
CoTreat...	GAP...	24	1		541	40	1628...	1436...		8.3	73...	83.9
CoTreat...	GAP...	24	2		620	98	619.3	8284.3		12.6	57.7	156.1
CoTreat...	GAP...	24	3		683	225	1635.9	2634...		15.1	23...	227.4
0.1X sa...	GAP...	25	1		540	39	13.2	1279.6		91.3	26...	0.6


C.



Peaks		Capillaries										
Sample	Primary	Cap	Peak	Name	Positi...	MW (...)	Height	Area	% Area	Width	S/N	Baseline
Control1	PDL-1	5	1		544	44	377.6	15401.7		38.3	40.6	131.5
Control1	PDL-1	5	2		603	79	987.5	34799.8		33.1	70.8	183.2
Control1	PDL-1	5	3		658	186	381.8	17284.3		42.5	22.1	237.0
Control1	PDL-1	6	1		602	80	597.3	62888.2		98.9	77.5	195.8
Treated1	PDL-1	7	1		607	84	818.3	24417.0		28.0	33.1	169.1
Treated2	PDL-1	10	1		604	78	689.8	17641.9		24.0	24.9	249.5
Treated2	PDL-1	10	2		682	231	421.0	10267.0		22.9	23.6	295.6
Stimula...	PDL-1	11	1		441	13	359.4	14058.2		36.8	53.8	168.5
Stimula...	PDL-1	11	2		585	62	331.5	14928.7		42.3	58.5	267.7
Stimula...	PDL-1	11	3		604	78	1612.3	76080.5		44.3	50.2	275.0
Stimula...	PDL-1	12	1		441	12	686.2	10324.7		14.1	52.3	140.8
Stimula...	PDL-1	12	2		585	63	1715.2	27172.5		14.9	59.9	244.0
Stimula...	PDL-1	12	3		603	79	1909.1	30474.4		15.0	59.9	255.6
Stimula...	PDL-1	12	4		683	239	426.3	6570.5		14.5	26.6	296.2
Stimula...	PDL-1	13	1		443	13	484.5	10267.7		19.9	39.4	155.2
Stimula...	PDL-1	13	2		587	62	935.5	24733.1		24.8	50.3	214.5
Stimula...	PDL-1	13	3		603	78	1948.6	55753.5		26.9	88.0	218.7
Stimula...	PDL-1	14	1		444	13	441.3	13867.3		29.5	54.9	158.5
Stimula...	PDL-1	14	2		589	62	639.7	24419.3		35.9	40.3	265.7
Stimula...	PDL-1	14	3		607	81	1787.3	67359.7		35.4	77.3	280.6
Stimula...	PDL-1	14	4		662	187	685.5	25012.9		34.3	21.4	327.2
Stimula...	PDL-1	14	5		679	227	0.0	0.3		29.9	28.2	341.8
Cotreat...	PDL-1	15	1		442	12	79.2	1985.3		23.6	12.3	107.2
Cotreat...	PDL-1	15	2		580	58	666.1	16145.8		22.8	53.5	169.4
Cotreat...	PDL-1	15	3		609	87	928.8	26715.9		27.0	77.3	185.5
Cotreat...	PDL-1	15	4		681	222	430.1	12300.1		26.9	31.0	227.9
COtreat...	PDL-1	16	1		581	60	444.4	15235.7		32.2	49.0	205.5
COtreat...	PDL-1	16	2		608	82	750.1	25864.7		32.4	56.3	229.2
COtreat...	PDL-1	16	3		683	231	0.0	0.3		31.9	24.5	296.9
Cotreat...	PDL-1	17	1		584	59	894.6	15593.6		16.4	41.4	134.2
Cotreat...	PDL-1	17	2		608	81	718.2	12669.9		16.6	19.1	136.6
Cotreat...	PDL-1	17	3		680	231	447.2	7774.3		16.3	20.5	141.9
Cotreat...	PDL-1	18	1		583	59	958.0	14968.0		14.7	54.6	107.8



D.



Peaks		Capillaries										
Sample	Primary	Cap	Peak	Name	Positi...	MW (...)	Height	Area	% Area	Width	S/N	Baseline
Control1	GAPDH	19	1		491	26	319.9	3073.5		9.0	69.7	96.8
Control1	GAPDH	19	2		532	38	1933...	1758672.6		8.5	52...	101.2
Control1	GAPDH	19	3		627	115	3057.8	33739.1		10.4	26...	107.8
Control1	GAPDH	19	4		678	226	1011...	119181.5		11.1	80...	109.9
Control1	GAPDH	19	5		690	249	1165...	142728.4		11.5	10...	110.3
Treated 1	GAPDH	20	1		538	40	1562...	1340560.5		8.1	31...	107.5
Treated 1	GAPDH	20	2		648	163	1383.8	23262.3		15.8	27.5	126.4
Treated 1	GAPDH	20	3		689	236	3906.7	80083.9		19.3	20...	131.0
Treated2	GAPDH	21	1		539	40	1534...	1306211.3		8.0	37...	89.3
Treated2	GAPDH	21	2		608	90	1086.7	19844.4		17.2	24.6	101.5
Treated2	GAPDH	21	3		648	158	1444.8	28237.5		18.4	31.1	106.9
Treated2	GAPDH	21	4		682	229	3295.1	72694.2		20.7	24...	110.9
Stimual...	GAPDH	22	1		490	26	441.2	4471.8		9.5	16...	64.7
Stimual...	GAPDH	22	2		536	39	1795...	1632468.4		8.5	72...	90.9
Stimual...	GAPDH	22	3		582	60	366.1	4256.2		10.9	20.3	124.1
Stimual...	GAPDH	22	4		628	117	1249.5	17118.1		12.9	67.4	162.2
Stimual...	GAPDH	22	5		646	149	1098.0	14568.9		12.5	44.8	178.0
Stimual...	GAPDH	22	6		678	225	1891.7	29158.2		14.5	26...	206.8
Cotreat...	GAPDH	23	1		540	39	1673...	1430883.5		8.0	59...	64.7
Cotreat...	GAPDH	23	2		619	99	1024.9	14406.8		13.2	30.5	75.0
Cotreat...	GAPDH	23	3		649	155	1258.2	18625.8		13.9	40.3	78.1
Cotreat...	GAPDH	23	4		679	221	2183.5	31538.0		13.6	19...	80.8
CoTreat...	GAPDH	24	1		541	40	1628...	1436378.5		8.3	73...	83.9
CoTreat...	GAPDH	24	2		620	98	619.3	8284.3		12.6	57.7	156.1
CoTreat...	GAPDH	24	3		683	225	1635.9	26348.9		15.1	23...	227.4
0.1X sa...	GAPDH	25	1		540	39	13.2	1279.6		91.3	26...	0.6

**Figure S4.** PD-L1 protein expression in TQ treated INF- $\gamma$  stimulated MDA-MB-468 TNBC cells. Following the overnight incubation period, cells were equally treated with 15  $\mu$ M of TQ for 24. A. Blot for PD-L1 protein expression in control, treated, stimulated and cotreated MDA-MB-468 cell. B. Blot for protein expression of GAPDH used for normalization. C. Blot for PD-L1 protein expression in control, treated, stimulated and cotreated MDA-MB-468 cell. D. Blot for protein expression of GAPDH used for normalization.